Borchmann, P; van Meerten, T; Bories, P; Dreger, P; Gopsca, L; Mutsaers, P; Edinger, M; Illes, A; von Tresckow, B; Neumeister, P; Steiner, N; Jaeger, U; Moreno, AT; Griskevicius, L; Iacoboni, G; Lemonnier, F; van Doesum, J; Shah, N; Orentas, R; Miltenyi, S; Overstijns, T; Bürger, I; Zadoyan, G; Brillant, C; van Heteren, P; Holtkamp, S; Vandenberghe, P.
Zamtocabtagene autoleucel, a tandem CD20-CD19 directed CAR-T cell therapy as second-line treatment for Relapsed/Refractory large B-cell lymphoma: primary analysis of the randomized, pivotal DALY 2-EU study
BLOOD. 2025; 146: 669-670.
Doi: 10.1182/blood-2025-669
Web of Science
FullText
FullText_MUG